Antiviral Drugs - Japan | Statista Market Forecast

The Antiviral Drugs market in Japan is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is projected to reach ¥US$1.84bn in 2024.
This growth is further expected to continue at a compound annual growth rate (CAGR 2024-2029) of 1.71%.
As a result, the market volume is anticipated to reach ¥US$2.00bn by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Antiviral Drugs market.
It is projected to reach a staggering US$30.64bn in 2024.
Japan's pharmaceutical industry is leading the way in the development of innovative antiviral drugs, with a strong focus on research and collaboration with international partners.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The demand for Antiviral Drugs in Japan has been increasing in recent years due to various factors.

Customer preferences: Japanese customers prefer Antiviral Drugs that are effective, safe, and have fewer side effects. They also prefer drugs that are easy to use and can be taken orally. Due to the aging population in Japan, there is a growing demand for drugs that can treat viral infections in elderly patients.

Trends in the market: One of the key trends in the Antiviral Drugs market in Japan is the increasing demand for drugs that can treat influenza. Influenza is a common viral infection in Japan, and there is a high demand for drugs that can effectively treat the symptoms of the disease. Another trend in the market is the increasing demand for drugs that can treat hepatitis C. Japan has one of the highest rates of hepatitis C in the world, and there is a growing need for effective treatments.

Local special circumstances: Japan has a well-established healthcare system, and the government plays an active role in regulating the pharmaceutical industry. The government has implemented various policies to promote the development and use of Antiviral Drugs in the country. For example, the government has provided subsidies for the development of new drugs and has implemented price controls to ensure that drugs are affordable for patients.

Underlying macroeconomic factors: The Antiviral Drugs market in Japan is influenced by various macroeconomic factors such as the aging population, the prevalence of viral infections, and the government's healthcare policies. Japan has one of the oldest populations in the world, and this has led to an increase in the demand for drugs that can treat age-related diseases. The prevalence of viral infections such as influenza and hepatitis C has also contributed to the growth of the Antiviral Drugs market in Japan. The government's healthcare policies have played a significant role in promoting the development and use of Antiviral Drugs in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.